Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01626092 · ClinicalTrials.gov registry record · NA
Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT01626092 is a NA study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 3 participants.
The verdict
NCT01626092, a NA study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) in patients with high-risk lysosomal and peroxisomal disorders using a novel conditioning regimen for hematopoietic cell transplantation (HCT). After a reduced-intensity conditioning regimen using volumetric-modulated arc therapy (VMAT)-delivered low-dose total body irradiation (TBI) with highly conformal marrow boosting, patients will be transplanted using either a related or unrelated allograft. The cell source may be marrow, peripheral blood or cord blood based on donor availability.
Interventions
- DRUG Melphalan
- DRUG Clofarabine
- BIOLOGICAL Hematopoietic stem cell transplantation
- DRUG Campath-1H
- RADIATION Total Body Irradiation with Marrow Boosting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-07-11 |
| Est. Completion | 2013-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01626092
The ClinicalTrials.gov registry entry for NCT01626092 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT01626092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01626092 about?
NCT01626092 is a clinical study titled "Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders". This study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) in patients with high-risk lysosomal and peroxisomal disorders using a novel conditioning regimen for hematopoietic cell transplantation (HCT). Afte...
What is the current status of trial NCT01626092?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2012-07-11. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01626092?
The interventions under investigation include: Melphalan (DRUG), Clofarabine (DRUG), Hematopoietic stem cell transplantation (BIOLOGICAL), Campath-1H (DRUG), Total Body Irradiation with Marrow Boosting (RADIATION).
Who is sponsoring clinical trial NCT01626092?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.